• 1
    Howden C, Hunt R. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 23308.
    Direct Link:
  • 2
    Malfertheiner P, Megraud F, O'Morain C, et al. The European Helicobacter pylori Study Group, current concepts in the management of H. pylori infection – the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 16780.
  • 3
    Huang J, Chiba N, Wilkinson JM. Which combination therapy can eradicate >90%Helicobacter pylori infection? A meta-analysis of amoxycillin, metronidazole, tetracycline, and clarithromycin containing regimens. Gastroenterology 1997; 112: A19 (Abstract).
  • 4
    Pipkin GA, Williamson R, Wood JR. One week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 82337.
  • 5
    Della-Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002; 16: 126975.
  • 6
    Peitz U, Sulliga M, Wolle M, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimindazole triple therapy to cue Helicobacter pylori infection: impact of two second-line therapies in a randomised study. Aliment Pharmacol Ther 2002; 16: 31524.
  • 7
    Pilotto A, Franceschi M, Rassau M, et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures of after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000; 32: 66772.
  • 8
    Toracchio S M, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998–2002. Dig Liver Dis 2003; 35: 5415.
  • 9
    Wang W, Wong B, Mukhopadhyay A, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000; 14: 90110.
  • 10
    Perez-Aldana L, Kato M, Nagagawa M, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 3069.
  • 11
    Duck WM, Sibel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 108894.
  • 12
    Grove D, Koutsouridis G. Increasing resistance of Helicobacter pylori to clarithromycin: is the horse bolting? Pathology 2002; 34: 713.
  • 13
    Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 55360.
  • 14
    Perri F, Festa V, Clemente R, Quitadamo R, Andruilli A. Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 3116.
  • 15
    Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: a preliminary experience. J Clin Gastroenterol 2000; 31: 2225.
  • 16
    Gisbert J, Pajares J. Helicobacter pylori‘rescue’ regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 6: 104757.
  • 17
    Heep M, Beck D, Bayerdorffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 14979.
  • 18
    Perri F, Festa V, Andriulli A. Treatment of antibiotic resistant Helicobacter pylori infection. N Engl J Med 1998; 339: 53.
  • 19
    Gisbert J, Calvet X, Bujanda L, Marcos S, Gisbert J, Pajares J. ‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8: 904.
  • 20
    Perri F, Festa V, Clemente R, Villani M, Quitadamo M, Caruso N. Randomized study of two ‘rescue’ therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 5862.
  • 21
    Bigard MA, Delchier JC, Raichi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxicillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 3838.
  • 22
    Wong BCY, Chang FY, Abid S, et al. Triple therapy with clarithromycin, omeprazole and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000; 14: 152935.
  • 23
    Perri F, Villani MR, Feta V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication after the standard ‘Maastricht triple therapy’. Aliment Pharmacol Ther 2001; 15: 10239.
  • 24
    Nagahara A, Miwa H, Okura R, et al. Strategy for re-treatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001; 16: 6138.
  • 25
    Gisbert J, Gisbert J, Marcos S, et al. Seven day rescue therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate. tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 13116.
  • 26
    Lee J, Breslin N, Hyde D, Buckley DK, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 48996.
  • 27
    Gisbert JP, Boixeda D, Mermajo F, et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999; 11: 104954.
  • 28
    Gomollon F, Ducons JA, Ferroro M, et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999; 4: 2225.
  • 29
    Boixeda D, Bermejo F, Martin-De-Argila C, et al. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 145760.
  • 30
    Laine L, Hunt R, El-Zimaity H, et al. Bismuth-base quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole and tetracycline given with omeprazole vs. omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 5627.
    Direct Link:
  • 31
    Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 916.